HGH Frag
Growth Hormone Fragment | Fat Loss Peptide
DoseGear research brief
HGH Fragment 176-191 is the fat-burning segment of human growth hormone, corresponding to amino acids 176 through 191 of the full GH molecule. It stimulates lipolysis and inhibits lipogenesis without the growth-promoting or insulin-disrupting effects associated with full-length HGH. AOD-9604 is a modified version of this fragment with an added N-terminal tyrosine residue.
Mimics the lipolytic region of human growth hormone by stimulating fat breakdown through beta-3 adrenergic receptor pathways. Unlike full HGH, it does not bind the growth hormone receptor, so it does not increase IGF-1 levels or interfere with glucose metabolism. The fragment selectively targets adipose tissue to promote fat oxidation.
Compound background
Study windows describe what researchers measured, not when an individual should expect a result.
C-terminal fragment of human growth hormone, related to but distinct from modified AOD-9604.
Experimental lipid-metabolism research with proposed lipolytic and antilipogenic activity.
Not reported in the reviewed compound-specific evidence.
Reference data
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
| Research context | Amount | Frequency | Route |
|---|---|---|---|
| Fat loss - Standard | 250mcg | Twice daily (morning fasted + pre-bed) | SubQ |
| Enhanced fat loss | 500mcg | Twice daily (morning fasted + pre-bed) | SubQ |
| Conservative start | 250mcg | Once daily (morning, fasted) | SubQ |
Reference cycle
8-12 weeks
Reference storage
Lyophilized: room temp or freezer long-term; Reconstituted: 2-8 degrees C for 28 days
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.
